Incretin Effect
Definition
The phenomenon whereby oral glucose ingestion stimulates a greater insulin response than intravenous glucose due to the release of incretin hormones such as GLP-1 and GIP from the gastrointestinal tract.
Incretin Effect
The incretin effect describes the observation that oral glucose administration provokes a substantially greater insulin secretory response from pancreatic beta cells than an equivalent amount of glucose delivered intravenously, despite achieving similar or even lower plasma glucose concentrations. This enhanced insulin response is attributed to the release of incretin hormones from the gastrointestinal tract during nutrient absorption. The two principal incretin hormones are glucagon-like peptide-1 (GLP-1), secreted by enteroendocrine L-cells primarily in the distal small intestine and colon, and glucose-dependent insulinotropic polypeptide (GIP), secreted by K-cells concentrated in the duodenum and proximal jejunum. Together, these hormones are estimated to account for 50-70% of the total insulin response to an oral glucose load in healthy individuals.
Both GLP-1 and GIP exert their insulinotropic effects by binding to specific G-protein-coupled receptors on pancreatic beta cells, stimulating cAMP production and potentiating glucose-stimulated insulin secretion. Importantly, this insulinotropic action is glucose-dependent, meaning it diminishes as blood glucose levels fall toward normal, thereby conferring an inherent safety mechanism against hypoglycemia. GLP-1 additionally suppresses glucagon secretion from alpha cells, delays gastric emptying, and promotes satiety through central nervous system signaling. Both incretin hormones are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), with native GLP-1 having a circulating half-life of only 1-2 minutes.
Clinical Relevance to Retatrutide
The incretin effect is diminished in individuals with type 2 diabetes, a phenomenon attributed in part to reduced GLP-1 secretion and impaired beta cell responsiveness to GIP. Retatrutide addresses this deficit by providing pharmacological activation of both the GLP-1 and GIP receptors at supraphysiological levels, effectively restoring and amplifying the incretin effect. By simultaneously engaging both incretin receptor pathways alongside glucagon receptor agonism, retatrutide leverages complementary mechanisms to enhance insulin secretion, improve glycemic control, and promote weight loss. The restoration of incretin signaling through exogenous receptor agonism has proven to be one of the most effective pharmacological strategies for the treatment of type 2 diabetes and obesity, and retatrutide’s triple-agonist design extends this approach to include additional metabolic benefits mediated by glucagon receptor activation.